Walter E. Washington Convention Center

Jun 15, 2025 7:00 AM - Jun 19, 2025 3:00 PM

801 Allen Y. Lew Place, NW, Washington, DC 20001-3614, USA

DIA 2025 Global Annual Meeting

Unintended Consequences: Effects of Inflation Reduction Act on the Future of Pharmaceutical Innovation

Session Chair(s)

Sarah  Martin, PhD, MS

Sarah Martin, PhD, MS

Senior Director - Global Regulatory Policy (Americas)

Eli Lilly and Company, United States

Among the largest areas of concern with the Inflation Reduction Act (IRA) are potential unintended consequences to pharmaceutical innovation. This forum will convene industry experts to explore the impact of and potential adjustments to the IRA.

Learning Objective : Discuss the unintended consequences of the IRA on innovation; Examine potential legislative solutions.

Speaker(s)

Gregory  Daniel, PhD, MPH

Panelist

Gregory Daniel, PhD, MPH

Eli Lilly and Company, United States

Vice President, Head of Public Policy Innovation and Evidence

Ryan  Gough

Industry Perspective

Ryan Gough

Woodberry Associates and PACH, United States

Partner, Senior Vice President, Public Affairs

Richard  Xie, PhD

The Impacts of the Inflation Reduction Act on Biopharmaceutical Investment Decisions

Richard Xie, PhD

RA Capital Management, United States

Senior Health Economist

Julie Ann Patterson, PharmD, PhD

Early Signals of IRA Impact: Theoretical and Observed Unintended Consequences

Julie Ann Patterson, PharmD, PhD

National Pharmaceutical Council, United States

Senior Director of Research

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.